Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention

Research output: Contribution to journalArticle

Standard

Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. / Lim, Hoong; Blann, Andrew; Chong, AY; Freestone, B; Lip, Gregory.

In: Diabetes Care, Vol. 27, No. 12, 01.12.2004, p. 2918-24.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{0f7671bebd1d429693bc22fc4c7135cf,
title = "Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention",
abstract = "OBJECTIVE: Vascular endothelial growth factor (VEGF) and angiopoietin (Ang)-1 and Ang-2 are mediators of angiogenesis. More recent data suggest that the balance between these growth factors may affect vascular endothelial integrity. Because diabetes is closely associated with endothelial perturbation, we studied plasma levels of these angiogenic growth factors in patients with diabetes; their relationship with glycemia, inflammation, and endothelial damage/dysfunction; and the effect of intensified cardiovascular risk management. RESEARCH DESIGN AND METHODS: We measured plasma VEGF, Ang-1, and Ang-2 alongside plasma von Willebrand factor (vWf) and urine albumin-to-creatinine ratio (marking endothelial damage/dysfunction) and interleukin (IL)-6 in 94 patients (38 with overt cardiovascular disease [CVD]) with diabetes and 34 normal control subjects. RESULTS: Plasma vWf (P=0.009), IL-6 (P ",
author = "Hoong Lim and Andrew Blann and AY Chong and B Freestone and Gregory Lip",
year = "2004",
month = dec,
day = "1",
doi = "10.2337/diacare.27.12.2918",
language = "English",
volume = "27",
pages = "2918--24",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association",
number = "12",

}

RIS

TY - JOUR

T1 - Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention

AU - Lim, Hoong

AU - Blann, Andrew

AU - Chong, AY

AU - Freestone, B

AU - Lip, Gregory

PY - 2004/12/1

Y1 - 2004/12/1

N2 - OBJECTIVE: Vascular endothelial growth factor (VEGF) and angiopoietin (Ang)-1 and Ang-2 are mediators of angiogenesis. More recent data suggest that the balance between these growth factors may affect vascular endothelial integrity. Because diabetes is closely associated with endothelial perturbation, we studied plasma levels of these angiogenic growth factors in patients with diabetes; their relationship with glycemia, inflammation, and endothelial damage/dysfunction; and the effect of intensified cardiovascular risk management. RESEARCH DESIGN AND METHODS: We measured plasma VEGF, Ang-1, and Ang-2 alongside plasma von Willebrand factor (vWf) and urine albumin-to-creatinine ratio (marking endothelial damage/dysfunction) and interleukin (IL)-6 in 94 patients (38 with overt cardiovascular disease [CVD]) with diabetes and 34 normal control subjects. RESULTS: Plasma vWf (P=0.009), IL-6 (P

AB - OBJECTIVE: Vascular endothelial growth factor (VEGF) and angiopoietin (Ang)-1 and Ang-2 are mediators of angiogenesis. More recent data suggest that the balance between these growth factors may affect vascular endothelial integrity. Because diabetes is closely associated with endothelial perturbation, we studied plasma levels of these angiogenic growth factors in patients with diabetes; their relationship with glycemia, inflammation, and endothelial damage/dysfunction; and the effect of intensified cardiovascular risk management. RESEARCH DESIGN AND METHODS: We measured plasma VEGF, Ang-1, and Ang-2 alongside plasma von Willebrand factor (vWf) and urine albumin-to-creatinine ratio (marking endothelial damage/dysfunction) and interleukin (IL)-6 in 94 patients (38 with overt cardiovascular disease [CVD]) with diabetes and 34 normal control subjects. RESULTS: Plasma vWf (P=0.009), IL-6 (P

U2 - 10.2337/diacare.27.12.2918

DO - 10.2337/diacare.27.12.2918

M3 - Article

C2 - 15562207

VL - 27

SP - 2918

EP - 2924

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

IS - 12

ER -